Švedska - švedščina - Läkemedelsverket (Medical Products Agency)

medac gesellschaft für klinische spezialpräparate mbh - vinorelbintartrat - koncentrat till infusionsvätska, lösning - 10 mg/ml - vinorelbintartrat 13,85 mg aktiv substans - vinorelbin

Švedska - švedščina - Läkemedelsverket (Medical Products Agency)

pfizer ab - fosfenytoinnatrium, vattenfritt - koncentrat till infusionsvätska, lösning/injektionsvätska, lösning - 75 mg/ml (50 mgfe/ml) - fosfenytoinnatrium, vattenfritt 75 mg aktiv substans - fosfenytoin

Švedska - švedščina - Läkemedelsverket (Medical Products Agency)

orifarm ab - fosfenytoinnatrium, vattenfritt - koncentrat till infusionsvätska, lösning/injektionsvätska, lösning - 75 mg/ml (50 mgfe/ml) - fosfenytoinnatrium, vattenfritt 75 mg aktiv substans

Švedska - švedščina - Läkemedelsverket (Medical Products Agency)

orifarm ab - fosfenytoinnatrium, vattenfritt - koncentrat till infusionsvätska, lösning/injektionsvätska, lösning - 75 mg/ml (50 mgfe/ml) - fosfenytoinnatrium, vattenfritt 75 mg aktiv substans

Švedska - švedščina - Läkemedelsverket (Medical Products Agency)

orifarm ab - fosfenytoinnatrium, vattenfritt - koncentrat till infusionsvätska, lösning/injektionsvätska, lösning - 75 mg/ml (50 mgfe/ml) - fosfenytoinnatrium, vattenfritt 75 mg aktiv substans

Evropska unija - švedščina - EMA (European Medicines Agency)

glaxo group ltd. - amprenavir - hiv-infektioner - antivirala medel för systemisk användning - ageneras, i kombination med andra antiretrovirala medel, är indicerat för behandling av proteasinhibitor (pi) erfarna hiv-1-infekterade vuxna och barn över 4 år. ageneraskapslar ska normalt ges med lågdos ritonavir som en farmakokinetisk förstärkare av amprenavir (se avsnitt 4. 2 och 4. valet av amprenavir bör baseras på individuell testning av virusresistens och behandlingshistorik hos patienter (se avsnitt 5. förmån av agenerase förstärkt med ritonavir har inte visats i pi långhuset patienter (se avsnitt 5.

Švedska - švedščina - Läkemedelsverket (Medical Products Agency)

accord healthcare b.v. - irinotekanhydrokloridtrihydrat - koncentrat till infusionsvätska, lösning - 20 mg/ml - irinotekanhydrokloridtrihydrat 20 mg aktiv substans; sorbitol hjälpämne

Švedska - švedščina - Läkemedelsverket (Medical Products Agency)

accord healthcare b.v. - atazanavirsulfat - kapsel, hård - 200 mg - laktosmonohydrat hjälpämne; propylenglykol hjälpämne; para-orange hjälpämne; atazanavirsulfat 227,805 mg aktiv substans

Švedska - švedščina - Läkemedelsverket (Medical Products Agency)

accord healthcare b.v. - atazanavirsulfat - kapsel, hård - 300 mg - propylenglykol hjälpämne; laktosmonohydrat hjälpämne; para-orange hjälpämne; atazanavirsulfat 341,708 mg aktiv substans

Evropska unija - švedščina - EMA (European Medicines Agency)

janssen-cilag international nv - darunavir - hiv-infektioner - antivirala medel för systemisk användning - prezista, co administered with low dose ritonavir is indicated in combination with other antiretroviral medicinal products for the treatment of human immunodeficiency virus (hiv 1) infection in adult and paediatric patients from the age of 3 years and at least 15 kg body weight. prezista, co administered with cobicistat is indicated in combination with other antiretroviral medicinal products for the treatment of human immunodeficiency virus (hiv 1) infection in adults and adolescents (aged 12 years and older, weighing at least 40 kg). in deciding to initiate treatment with prezista co administered with cobicistat or low dose ritonavir, careful consideration should be given to the treatment history of the individual patient and the patterns of mutations associated with different agents. genotypic or phenotypic testing (when available) and treatment history should guide the use of prezista. prezista, co administered with low dose ritonavir is indicated in combination with other antiretroviral medicinal products for the treatment of patients with human immunodeficiency virus (hiv 1) infection. prezista 75 mg, 150 mg, and 600 mg tablets may be used to provide suitable dose regimens:for the treatment of hiv 1 infection in antiretroviral treatment (art) experienced adult patients, including those that have been highly pre treated. for the treatment of hiv 1 infection in paediatric patients from the age of 3 years and at least 15 kg body weight. in deciding to initiate treatment with prezista co administered with low dose ritonavir, careful consideration should be given to the treatment history of the individual patient and the patterns of mutations associated with different agents. genotypic or phenotypic testing (when available) and treatment history should guide the use of prezista. prezista, co administered with low dose ritonavir is indicated in combination with other antiretroviral medicinal products for the treatment of patients with human immunodeficiency virus (hiv 1) infection. prezista, co administered with cobicistat is indicated in combination with other antiretroviral medicinal products for the treatment of human immunodeficiency virus (hiv 1) infection in adults and adolescents (aged 12 years and older, weighing at least 40 kg). prezista 400 mg and 800 mg tablets may be used to provide suitable dose regimens for the treatment of hiv 1 infection in adult and paediatric patients from the age of 3 years and at least 40 kg body weight who are:antiretroviral therapy (art) naïve. art experienced with no darunavir resistance associated mutations (drv rams) and who have plasma hiv 1 rna < 100,000 copies/ml and cd4+ cell count ≥ 100 cells x 106/l. in deciding to initiate treatment with prezista in such art experienced patients, genotypic testing should guide the use of prezista.